Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.61 |
| ▸ | ME2 | P23368 | 5/20 | 0.46 |
| ▸ | ME1 | P48163 | 5/20 | 0.46 |
| ▸ | ME3 | Q16798 | 5/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556144 | 0.81 | HCAR2 (0.50) | HCAR2ME2ME1ME3EGLN1 | |
| SCHEMBL4548329 | 0.77 | HCAR2 (1.00) | HCAR2CYP2C9 | |
| SCHEMBL4556142 | 0.75 | HCAR2 (0.77) | HCAR2ME2ME1ME3CYP2C9 | |
| SCHEMBL4556145 | 0.74 | HCAR2 (0.75) | HCAR2ME2ME1ME3CYP2C9 | |
| SCHEMBL4548413 | 0.70 | HCAR2 (0.44) | HCAR2EGLN1CYP2C9 | |
| SCHEMBL12989502 | 0.69 | EGLN1 (0.47) | HCAR2ME2ME1ME3EGLN1 | |
| SCHEMBL31435193 | 0.69 | HCAR2 (0.39) | HCAR2ME2ME1ME3EGLN1 | |
| SCHEMBL11899892 | 0.69 | EGLN1 (0.44) | EGLN1 | |
| SCHEMBL4414182 | 0.67 | MEN1 (0.48) | P4HTM | |
| SCHEMBL11900004 | 0.67 | EPHX2 (0.44) | HCAR2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | HCAR2 2/4885ME2 1186/4885ME1 1463/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | HCAR2 2/4885ME2 1229/4885ME1 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.